Cencora, Inc. Quarterly Report for Q1 Ended Dec 31, 2024

Summary

Cencora, Inc. reported strong revenue growth in the fourth quarter of fiscal year 2024, with a 12.8% increase year-over-year, driven primarily by its U.S. Healthcare Solutions segment. This growth was bolstered by significant sales of GLP-1 class products for diabetes and weight loss, as well as increased specialty product sales. Despite the revenue surge, net income attributable to Cencora, Inc. saw a decline to $488.6 million from $601.5 million in the prior year's comparable period, leading to a decrease in diluted earnings per share from $2.98 to $2.50. This profitability dip can be attributed to higher operating expenses, including increased litigation and opioid-related expenses, and a decrease in gains from antitrust litigation settlements. The company also completed a significant acquisition of Retina Consultants of America (RCA) for $4.4 billion in early January 2025, further impacting its financial position and future growth trajectory.

Key Highlights

• 1Revenue increased by 12.8% year-over-year to $81.5 billion, driven by a 13.6% increase in the U.S. Healthcare Solutions segment.
• 2Sales of GLP-1 class products for diabetes and weight loss contributed $3.2 billion in increased revenue.
• 3Net income attributable to Cencora, Inc. decreased to $488.6 million from $601.5 million in the prior year's quarter.
• 4Diluted earnings per share declined to $2.50 from $2.98 year-over-year.
• 5Operating expenses increased by 12.5%, notably due to higher litigation and opioid-related expenses compared to a credit in the prior year.
• 6Cencora completed the acquisition of Retina Consultants of America (RCA) for $4.4 billion in early January 2025.
• 7The company repurchased $385.4 million of its common stock during the quarter and increased its quarterly dividend by 8%.

Frequently Asked Questions